Member Info for WeTookPelham

Mind you with the new variant that seems to be causing some concern, Scancell may need to dust covidity down still?

Ah yes the Cambridge university one it seems, sorry. I got all excited there! But we know sclp seem to have put covidity on the shelf for any potential suitors, so in hindsight it was unlikely to be Sclp.

Who else is needle-less and multi variant?

"...We are looking for volunteers for a first in human, needleless vaccine study that could protect against multiple coronavirus variants."

Sounds familiar?

https://www.dailyecho.co.uk/news/23477463.southampton-volunteers-needed-covid-vaccine-study-without-needles/

Thoughts??

https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-annual-profit-forecast-humira-demand-holds-steady-2023-04-27/

Another big pharma with patent cliff issues.

@wigwammer RE " I am hoping that the delay may be related to the time required to get option incentives in place, but if so, that’s a bit naff…"

Interesting point, I did wonder the timing of the recent options RNS.

"AB, Good post!…eternal optimism should be tempered with an occasional “what if”?"

Give it 5min, crackin will be along to predict 5p again.

But (semi) joking aside, of course it is important debate the "if's". However in this case, from what we know officially and unofficially, the trial results look promising, do they not? Genuine question.

My point is AB124, you are not the self appointed paragon of balance you seem to think you are. IMO.

And just to add we have professor Durant confirm results of certain McMillan thread posters.

AB124 - genuine question are you invested here?

Also do you think Dr Jean Michel Cosery would have joined if they had dud products?

Would they have gone AACR if results were not good? Or at the very least stable?

Balance? Umm yeah ok.

*before we get an update.
I was using your quote as it's a nice summary.

Hi TF, not a pop at you, more the posters who think it will be years beige we get a significant update.

RE EmptyEnd's and Chester18's most recent posts, and what was said at the AGM about the fact that updates can (and hopefully should) being given frequently due to the nature of the trial.

Well, it somewhat dispels the "virtuous calls for patience " does it not.

https://www.bloomberg.com/news/articles/2023-04-24/china-s-covid-drugmakers-surge-amid-concern-over-new-wave

TF - very well put.

Also "Virtuous calls for patience" made me smile, we seem to get a lot of that here, odd that?

To add to my original point, why did Scancell provide an 8 week update? They didn't necessarily have to, did they?
https://www.lse.co.uk/rns/SCLP/encouraging-early-efficacy-data-from-modify-trial-nuxyhn2pyg50fgf.html

So with that in mind why isn't a 16 week update just as likely?

....being very *quiet with news relases all things considered*
(overzelous swear filter).

The truth is we don't know when Scancell will update the market RE trial results, too say there is a long way to go is not a given IMO, in the same way trial news soon isn't a given.
Also why is no-one the mentioning potential left field (non trial) news, e.g. another mabs deal, covidity, licensing. partenerships etc.
As someone else wrote, considering how much is going on with Scancell in the background right at this very moment, they are inversely (and curiously) being very sp**** with news releases.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088229/

Why now is my question, couldn't this have happened closer to when he started his role?

Any thoughts/views on this?